Overview
- Third-quarter revenue rose about 3% to nearly €5.5 billion.
- Adjusted EBIT increased 4% to €574 million (up 6% at constant currencies), and adjusted net profit reached €351 million from €312 million a year earlier.
- Fresenius raised its full-year guidance to 4–8% adjusted EBIT growth at constant exchange rates.
- Kabi drove the quarter’s gains, while the Helios clinics business posted earnings declines.
- The company is seeking exclusions for generics and biosimilars in a pending U.S. Section 232 tariff review that could affect its North American operations, and it kept the revenue target raised in the summer.